Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Vascular endothelium is responsible for the secretion of several substances exerting anti-atherogenic effects. Endothelial damage is also crucial for the progress of atherosclerosis and risk factors for atherosclerosis represent crucial factors associated with endothelial dysfunction. Studies have shown that patients with cardiovascular disease are characterized by impaired endothelial function (EF). Therefore, several agents have been proposed as potential modulators of EF. Most of the available approaches include pharmaceutical agents routinely used such as statins, angiotensin converting enzyme inhibitors, antioxidants, L-arginine, insulin sensitizers or others still under investigation such as tetrahydrobiopterin or folic acid (folate). Despite of the fact that there are several strategies aiming to improve endothelial dysfunction by enhancing nitric oxide bioavailability, it is still unclear whether they could be beneficial at a clinical level.

Type

Journal article

Journal

Minerva Med

Publication Date

08/2010

Volume

101

Pages

271 - 284

Keywords

Angiotensin-Converting Enzyme Inhibitors, Antioxidants, Atherosclerosis, Biopterin, Cardiovascular Diseases, Endothelium, Vascular, Folic Acid, Genetic Therapy, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Insulin Resistance, Nitric Oxide, Risk Factors